Growth Metrics

Innoviva (INVA) Shares Outstanding (Weighted Average) (2009 - 2026)

Innoviva posted quarterly Shares Outstanding (Weighted Average) of $74.2 million for Q1 2026, up 18.26% year-on-year from $62.7 million in Q1 2025, and up 10.04% on a QoQ basis from $67.4 million in Q4 2025.

Innoviva (INVA) has 18 years of Shares Outstanding (Weighted Average) data on file, last reported at $74.2 million in Q1 2026.

  • For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 18.26% year-over-year to $74.2 million; the trailing twelve-month figure through Mar 2026 stood at $74.2 million (up 18.26% YoY), and the FY2025 full-year result was $67.4 million, up 7.44% from the prior year.
  • Shares Outstanding (Weighted Average) for Q1 2026 stood at $74.2 million, up from $67.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $74.2 million in Q1 2026 and bottomed at $62.6 million in Q3 2024.
  • The 5-year median for Shares Outstanding (Weighted Average) is $65.4 million (2023), against an average of $66.3 million.
  • The widest annual swing landed in 2022, when Shares Outstanding (Weighted Average) slumped 31.39%; it then grew 18.26% in 2026.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $69.6 million in 2022, then declined by 6.04% to $65.4 million in 2023, then decreased by 4.14% to $62.7 million in 2024, then increased by 7.44% to $67.4 million in 2025, then advanced by 10.04% to $74.2 million in 2026.
  • The last three Shares Outstanding (Weighted Average) figures came in at $74.2 million (Q1 2026), $67.4 million (Q4 2025), and $64.9 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares (Weighted Avg.) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 177,333.76 Bn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 185,491.37 Bn
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 100.00 Bn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 55.66 Bn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 118.76 Bn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 254.10 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - 16.04 Bn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 104.00 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 132.89 Mn
10 Innoviva 1.60 Bn 992.84 Mn 75.83 Mn 74.16 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 74.16 Mn
Dec 31, 2025 67.40 Mn
Sep 30, 2025 64.90 Mn
Jun 30, 2025 62.87 Mn
Mar 31, 2025 62.71 Mn
Dec 31, 2024 62.73 Mn
Sep 30, 2024 62.57 Mn
Jun 30, 2024 62.86 Mn
Mar 31, 2024 63.19 Mn
Dec 31, 2023 65.44 Mn
Sep 30, 2023 64.95 Mn
Jun 30, 2023 66.56 Mn
Mar 31, 2023 67.79 Mn
Dec 31, 2022 69.64 Mn
Sep 30, 2022 69.64 Mn
Jun 30, 2022 69.64 Mn
Mar 31, 2022 69.54 Mn
Dec 31, 2021 82.06 Mn
Sep 30, 2021 69.46 Mn
Jun 30, 2021 94.86 Mn
Mar 31, 2021 101.37 Mn
Dec 31, 2020 101.32 Mn
Sep 30, 2020 101.36 Mn
Jun 30, 2020 101.28 Mn
Mar 31, 2020 101.24 Mn
Dec 31, 2019 101.15 Mn
Sep 30, 2019 101.19 Mn
Jun 30, 2019 101.15 Mn
Mar 31, 2019 101.06 Mn
Dec 31, 2018 100.85 Mn
Sep 30, 2018 100.94 Mn
Jun 30, 2018 100.87 Mn
Mar 31, 2018 100.60 Mn
Dec 31, 2017 106.95 Mn
Sep 30, 2017 106.84 Mn
Jun 30, 2017 107.47 Mn
Mar 31, 2017 107.49 Mn
Dec 31, 2016 110.28 Mn
Sep 30, 2016 111.13 Mn
Jun 30, 2016 112.01 Mn
Mar 31, 2016 112.48 Mn
Dec 31, 2015 115.37 Mn
Sep 30, 2015 115.38 Mn
Jun 30, 2015 115.33 Mn
Mar 31, 2015 114.66 Mn
Dec 31, 2014 112.06 Mn
Sep 30, 2014 113.10 Mn
Jun 30, 2014 110.97 Mn
Mar 31, 2014 109.86 Mn
Dec 31, 2013 102.43 Mn
Sep 30, 2013 100.32 Mn
Jun 30, 2013 96.96 Mn
Mar 31, 2013 99.18 Mn
Dec 31, 2012 90.91 Mn
Sep 30, 2012 89.27 Mn
Jun 30, 2012 89.02 Mn
Mar 31, 2012 83.59 Mn
Dec 31, 2011 82.05 Mn
Sep 30, 2011 81.78 Mn
Jun 30, 2011 81.81 Mn
Mar 31, 2011 80.85 Mn
Dec 31, 2010 72.07 Mn
Sep 30, 2010 70.68 Mn
Jun 30, 2010 73.28 Mn
Dec 31, 2009 63.08 Mn